Open AccessThe long non‐coding RNA SPRY 4‐ IT 1: An emerging player in tumorigenesis and osteosarcoma
Author(s) -
Li Zheng,
Shen Jianxiong,
Chan Matthew T. V.,
Wu William Ka Kei
Publication year - 2018
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.12446
Subject(s) - carcinogenesis , oncogene , cancer , long non coding rna , cancer research , biology , rna , osteosarcoma , gene , genetics , cell cycle
Accumulating evidence from genome‐wide analysis and functional studies has begun to unveil the important role of long non‐coding RNA s (lnc RNA s) in cancer development. The lnc RNA SPRY 4‐ IT 1 is derived from an intron of SPRY 4 gene and was originally reported to be upregulated in melanoma in which it functioned as an oncogene. Since this discovery, an increasing number of studies have investigated the expression and function of SPRY 4‐ IT 1 in human cancers. Aberrant expression of SPRY 4‐ IT 1 has now been documented in different cancer types, including osteosarcoma, breast, renal, oesophageal and prostate cancers. However, its deregulation and function in lung and gastric cancers remain controversial. Pertinent to clinical practice, SPRY 4‐ IT 1 expression has been shown to predict survival of cancer patients. In this review, we summarize recent evidence concerning SPRY 4‐ IT 1 deregulation and the associated mechanisms in human cancers. We also discuss the potential clinical utilization of this lnc RNA as a diagnostic and prognostic biomarker for cancer patients.